Life sciences company Aditx Therapeutics, Inc. (ADTX) announced Monday that it has submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens.
The granting of an EUA by the FDA would allow Aditx to commercially distribute AditxtScore for COVID-19 throughout the country.
AditxtScore for COVID-19 is a double-multiplex assay that can be used to detect and differentiate various antibody isotypes against multiple SARS-CoV-2 antigens simultaneously in a single reaction.
Currently, one of the most widely used platforms, ELISA, can only detect one antibody isotype against one antigen at a time. AditxtScore for COVID-19 increases the resolution of results obtained for each antibody isotype thereby enhancing sensitivity for monitoring changes in these values over time.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.